SIRPA and neoplasm: In the last few decades, engineered macrophages with the blockage of CD 47‐SIRPα recognition have shown promising efficacy to reduce tumor growth in non‐Hodgkin lymphoma (NHL), acute lymphoblastic leukemia, acute myeloid leukemia, and myeloma.12